Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · IEX Real-Time Price · USD
6.15
-0.23 (-3.61%)
At close: Jul 19, 2024, 4:00 PM
6.22
+0.07 (1.14%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

Cytek Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Revenue
200.79193.02164.04127.9592.8457.88
Revenue Growth (YoY)
20.91%17.67%28.20%37.82%60.39%-
Cost of Revenue
89.3983.5963.0648.8141.1329.21
Gross Profit
111.4109.43100.9779.1451.7128.67
Selling, General & Admin
93.8593.1267.9245.5524.3616.98
Research & Development
43.9744.1534.8624.4413.698.93
Other Operating Expenses
0000020.02
Operating Expenses
137.82137.27102.7869.9938.0545.93
Operating Income
-26.42-27.85-1.89.1613.66-17.26
Interest Expense / Income
1.842.072.571.740.330
Other Expense / Income
-12.6-14.21-5.731.5-1.1-0.96
Pretax Income
-15.66-15.711.355.9114.43-16.29
Income Tax
-4.15-3.56-1.222.91-4.980.53
Net Income
-11.51-12.152.58319.41-16.83
Preferred Dividends
000316.20
Net Income Common
-11.51-12.152.5803.22-16.83
Shares Outstanding (Basic)
131135135772921
Shares Outstanding (Diluted)
131135139823321
Shares Change
-3.37%-2.37%69.93%150.13%55.61%-
EPS (Basic)
-0.09-0.090.02-0.11-0.80
EPS (Diluted)
-0.09-0.090.02-0.10-0.80
Free Cash Flow
1.490.45-22.10.2713.61-14.72
Free Cash Flow Per Share
0.010.00-0.160.000.47-0.70
Gross Margin
55.48%56.69%61.56%61.86%55.70%49.54%
Operating Margin
-13.16%-14.43%-1.10%7.16%14.71%-29.81%
Profit Margin
-5.73%-6.29%1.57%-3.46%-29.07%
Free Cash Flow Margin
0.74%0.24%-13.47%0.21%14.66%-25.43%
Effective Tax Rate
---90.53%49.24%-34.52%-
EBITDA
-3.93-4.419.588.915.37-15.98
EBITDA Margin
-1.96%-2.28%5.84%6.95%16.55%-27.61%
Depreciation & Amortization
9.899.235.661.240.60.31
EBIT
-13.82-13.643.937.6514.76-16.29
EBIT Margin
-6.88%-7.07%2.39%5.98%15.90%-28.15%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).